Lumos Diagnostics Holdings (ASX:LDX) ROCE % : -65.92% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Lumos Diagnostics Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Lumos Diagnostics Holdings's annualized ROCE % for the quarter that ended in Dec. 2023 was -65.92%.

Lumos Diagnostics Holdings ROCE % Historical Data

The historical data trend for Lumos Diagnostics Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumos Diagnostics Holdings ROCE % Chart

Lumos Diagnostics Holdings Annual Data

Trend

Jun22

Jun23

ROCE %

-188.92

-42.71

Lumos Diagnostics Holdings Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial			-30.19	-243.07	-66.56	-27.59	-65.92

Lumos Diagnostics Holdings ROCE % Calculation

Lumos Diagnostics Holdings's annualized ROCE % for the fiscal year that ended in Jun. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2023 )		(A: Jun. 2022 )		(A: Jun. 2023 )
	=	-12.814	/	( ( (52.566 - 18.256)	+	(37.874 - 12.179) )	/ 2 )
	=	-12.814	/	( (34.31	+	25.695)	/ 2 )
	=	-12.814	/	30.0025
	=	-42.71 %

Lumos Diagnostics Holdings's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-16.766	/	( ( (37.874 - 12.179)	+	(34.44 - 9.269) )	/ 2 )
	=	-16.766	/	( ( 25.695	+	25.171 )	/ 2 )
	=	-16.766	/	25.433
	=	-65.92 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Lumos Diagnostics Holdings (ASX:LDX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Lumos Diagnostics Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Lumos Diagnostics Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumos Diagnostics Holdings (ASX:LDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Lumos Diagnostics Holdings Ltd (ASX:LDX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

LDXHF:USA

Address

2724 Loker Ave West, Carlsbad, CA, USA, 92010

Website

https://www.lumosdiagnostics.com

Lumos Diagnostics Holdings Ltd is engaged in the development, manufacture and distribution of point-of-care diagnostic (POC) tests and associated readers for analysis of POC diagnostic tests. It also directly develops, manufactures and commercializes proprietary, Lumos-branded POC tests that target infectious and inflammatory diseases. It generates maximum revenue from the commercial services and solutions relating to POC diagnostic tests.

Lumos Diagnostics Holdings (ASX:LDX) Headlines

No Headlines